These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 36604598)

  • 21. The C-terminal tails of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and Fas receptors have opposing functions in Fas-associated death domain (FADD) recruitment and can regulate agonist-specific mechanisms of receptor activation.
    Thomas LR; Johnson RL; Reed JC; Thorburn A
    J Biol Chem; 2004 Dec; 279(50):52479-86. PubMed ID: 15452120
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5.
    Adams C; Totpal K; Lawrence D; Marsters S; Pitti R; Yee S; Ross S; Deforge L; Koeppen H; Sagolla M; Compaan D; Lowman H; Hymowitz S; Ashkenazi A
    Cell Death Differ; 2008 Apr; 15(4):751-61. PubMed ID: 18219321
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mutations Enhancing Selectivity of Antitumor Cytokine TRAIL to DR5 Receptor Increase Its Cytotoxicity against Tumor Cells.
    Gasparian ME; Bychkov ML; Yagolovich AV; Dolgikh DA; Kirpichnikov MP
    Biochemistry (Mosc); 2015 Aug; 80(8):1080-91. PubMed ID: 26547077
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Direct binding of Fas-associated death domain (FADD) to the tumor necrosis factor-related apoptosis-inducing ligand receptor DR5 is regulated by the death effector domain of FADD.
    Thomas LR; Henson A; Reed JC; Salsbury FR; Thorburn A
    J Biol Chem; 2004 Jul; 279(31):32780-5. PubMed ID: 15173180
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Structural basis of LaDR5, a novel agonistic anti-death receptor 5 (DR5) monoclonal antibody, to inhibit DR5/TRAIL complex formation.
    Qiao C; Hu M; Guo L; Lv M; Lin Z; Geng J; Lang X; Li X; Li Y; Ma Y; Feng J; Shen B
    BMC Immunol; 2012 Jul; 13():40. PubMed ID: 22788777
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel Immunoliposome Technology for Enhancing the Activity of the Agonistic Antibody against the Tumor Necrosis Factor Receptor Superfamily.
    Niwa T; Kasuya Y; Suzuki Y; Ichikawa K; Yoshida H; Kurimoto A; Tanaka K; Morita K
    Mol Pharm; 2018 Sep; 15(9):3729-3740. PubMed ID: 29648839
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dual role of DR5 in death and survival signaling leads to TRAIL resistance in cancer cells.
    Shlyakhtina Y; Pavet V; Gronemeyer H
    Cell Death Dis; 2017 Aug; 8(8):e3025. PubMed ID: 29048428
    [TBL] [Abstract][Full Text] [Related]  

  • 28. DR4 specific TRAIL variants are more efficacious than wild-type TRAIL in pancreatic cancer.
    Yu R; Albarenque SM; Cool RH; Quax WJ; Mohr A; Zwacka RM
    Cancer Biol Ther; 2014; 15(12):1658-66. PubMed ID: 25482930
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synthetic ligands of death receptor 5 display a cell-selective agonistic effect at different oligomerization levels.
    Beyrath J; Chekkat N; Smulski CR; Lombardo CM; Lechner MC; Seguin C; Decossas M; Spanedda MV; Frisch B; Guichard G; Fournel S
    Oncotarget; 2016 Oct; 7(40):64942-64956. PubMed ID: 27409341
    [TBL] [Abstract][Full Text] [Related]  

  • 30.
    Baudin A; Guichard A; Collie GW; Rousseau S; Chaignepain S; Hocquellet A; Berbon M; Loquet A; Mackereth C; Guichard G; Odaert B
    Biomol NMR Assign; 2018 Oct; 12(2):309-314. PubMed ID: 29869749
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ewing's sarcoma family tumors are sensitive to tumor necrosis factor-related apoptosis-inducing ligand and express death receptor 4 and death receptor 5.
    Mitsiades N; Poulaki V; Mitsiades C; Tsokos M
    Cancer Res; 2001 Mar; 61(6):2704-12. PubMed ID: 11289151
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibition of euchromatin histone-lysine N-methyltransferase 2 sensitizes breast cancer cells to tumor necrosis factor-related apoptosis-inducing ligand through reactive oxygen species-mediated activating transcription factor 4-C/EBP homologous protein-death receptor 5 pathway activation.
    Kim SY; Hong M; Heo SH; Park S; Kwon TK; Sung YH; Oh Y; Lee S; Yi GS; Kim I
    Mol Carcinog; 2018 Nov; 57(11):1492-1506. PubMed ID: 29964331
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Developing TRAIL/TRAIL death receptor-based cancer therapies.
    Yuan X; Gajan A; Chu Q; Xiong H; Wu K; Wu GS
    Cancer Metastasis Rev; 2018 Dec; 37(4):733-748. PubMed ID: 29541897
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Generation of new TRAIL mutants DR5-A and DR5-B with improved selectivity to death receptor 5.
    Gasparian ME; Chernyak BV; Dolgikh DA; Yagolovich AV; Popova EN; Sycheva AM; Moshkovskii SA; Kirpichnikov MP
    Apoptosis; 2009 Jun; 14(6):778-87. PubMed ID: 19412666
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tumor necrosis factor-related apoptosis inducing ligand (TRAIL) up-regulates death receptor 5 (DR5) mediated by NFkappaB activation in epithelial derived cell lines.
    Shetty S; Gladden JB; Henson ES; Hu X; Villanueva J; Haney N; Gibson SB
    Apoptosis; 2002 Oct; 7(5):413-20. PubMed ID: 12207174
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Modulation of TRAIL resistance in colon carcinoma cells: different contributions of DR4 and DR5.
    van Geelen CM; Pennarun B; Le PT; de Vries EG; de Jong S
    BMC Cancer; 2011 Jan; 11():39. PubMed ID: 21272366
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of activating transcription factor 3 (ATF3) in endoplasmic reticulum (ER) stress-induced sensitization of p53-deficient human colon cancer cells to tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis through up-regulation of death receptor 5 (DR5) by zerumbone and celecoxib.
    Edagawa M; Kawauchi J; Hirata M; Goshima H; Inoue M; Okamoto T; Murakami A; Maehara Y; Kitajima S
    J Biol Chem; 2014 Aug; 289(31):21544-61. PubMed ID: 24939851
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Etoposide and doxorubicin enhance the sensitivity of triple negative breast cancers through modulation of TRAIL-DR5 axis.
    Das S; Tripathi N; Siddharth S; Nayak A; Nayak D; Sethy C; Bharatam PV; Kundu CN
    Apoptosis; 2017 Oct; 22(10):1205-1224. PubMed ID: 28702823
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in established and primary glioma cell lines.
    Jaganathan J; Petit JH; Lazio BE; Singh SK; Chin LS
    Neurosurg Focus; 2002 Sep; 13(3):ecp1. PubMed ID: 15844877
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tumor-derived mutations in the TRAIL receptor DR5 inhibit TRAIL signaling through the DR4 receptor by competing for ligand binding.
    Bin L; Thorburn J; Thomas LR; Clark PE; Humphreys R; Thorburn A
    J Biol Chem; 2007 Sep; 282(38):28189-94. PubMed ID: 17666396
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.